Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients, \>/= 6 years of age~* Confirmed diagnosis of cystic fibrosis (CF)~* Receiving Pulmozyme once daily chronically for treatment of CF for at least 6 months prior to screening~* Percent predicted FEV1 \>/= 40% at screening based on the Wang (males \< 18 years, females \< 16 years) or Hankinson (males \>/= 18 years, females \>/= 16 years) standardized equations~* Able to reproducibly perform spirometry testing and comply with study assessments~Exclusion Criteria:~* An acute respiratory infection or pulmonary exacerbation within 4 weeks prior to randomization~* Initiation of any new chronic therapy (e.g. inhaled corticosteroids, inhaled oral antibiotics, high-dose ibuprofen, hypertonic saline, ivacaftor) for respiratory disease within 4 weeks prior to randomization~* Changes in chest physiotherapy schedule within 4 weeks prior to randomization~* Hospitalization within 4 weeks prior to randomization~* Planned hospitalization during the 6-week study~* History of organ transplantation~* Participation in an investigational drug or device study within 30 day prior to screening

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eRapid Nebulizer (Type: EXPERIMENTAL): Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
- Jet Nebulizer (Type: ACTIVE_COMPARATOR): Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).